Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C65H85N17O12.C2H4O2 |
Molecular Weight | 1356.5291 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=C(C)NC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=C5C=CC=C6)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8
InChI
InChIKey=MQOAHMYIJGUWMT-JESVGHGASA-N
InChI=1S/C65H85N17O12.C2H4O2/c1-5-69-63(93)54-17-11-25-82(54)64(94)47(16-10-24-70-65(66)67)75-57(87)48(26-35(2)3)76-61(91)52(30-43-36(4)73-45-15-9-7-13-42(43)45)80-58(88)49(27-37-18-20-40(84)21-19-37)77-62(92)53(33-83)81-59(89)50(28-38-31-71-44-14-8-6-12-41(38)44)78-60(90)51(29-39-32-68-34-72-39)79-56(86)46-22-23-55(85)74-46;1-2(3)4/h6-9,12-15,18-21,31-32,34-35,46-54,71,73,83-84H,5,10-11,16-17,22-30,33H2,1-4H3,(H,68,72)(H,69,93)(H,74,85)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,86)(H,80,88)(H,81,89)(H4,66,67,70);1H3,(H,3,4)/t46-,47-,48-,49-,50-,51-,52+,53-,54-;/m0./s1
Molecular Formula | C65H85N17O12 |
Molecular Weight | 1296.4771 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 3 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10569560Curator's Comment: description was created based on several sources, including:
DOI: 10.1023/A:1008898216113 | https://www.ncbi.nlm.nih.gov/pubmed/16939388
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10569560
Curator's Comment: description was created based on several sources, including:
DOI: 10.1023/A:1008898216113 | https://www.ncbi.nlm.nih.gov/pubmed/16939388
Avorelin is a superagonist of natural luteinizing-hormone-releasing-hormone. Avorelin has been formulated in high molecular weight polylactic glycolic acid to afford protracted and continuous release of the peptide from subcutaneous implants. Avorelin has been in phase II clinical trials by Mediolanum for the treatment of prostate cancer, breast cancer and endometriosis. However, this research has been discontinued. Adverse events mainly related to androgen suppression (hot flushes, decreased libido and impotence) or the nature of the disease (skeletal pain).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1855 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10569560 DOI: 10.1023/A:1008898216113 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Manipulation of postnatal testosterone levels affects phallic and clitoral development in infant rhesus monkeys. | 1999 Apr |
|
Investigation of the role of postnatal testosterone in the expression of sex differences in behavior in infant rhesus macaques (Macaca mulatta). | 1999 Apr |
|
Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. Avorelin Study Group. | 1999 Dec |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:58:43 GMT 2023
by
admin
on
Fri Dec 15 15:58:43 GMT 2023
|
Record UNII |
3575L4873R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40229177
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
PRIMARY | |||
|
3575L4873R
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
PRIMARY | |||
|
C99155
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
PRIMARY | |||
|
785814-29-1
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
PRIMARY | |||
|
71587800
Created by
admin on Fri Dec 15 15:58:43 GMT 2023 , Edited by admin on Fri Dec 15 15:58:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |